NR4A1 and breast cancer: The predictive markers in this study are currently mostly relevant for patients with advanced disease; some markers require additional pathological information (eg, hormone receptor status for PIK3CA mutations in breast cancer), and other findings can guide later-line treatment options after prior standard-of-care therapy.